Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials In this pilot study, we assessed the ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with ...
Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...
A phase 1/2 study of RTX-224, an engineered red blood cell expressing 4-1BB ligand and membrane-bound IL-12, for the treatment of patients with select advanced solid tumors. This is an ASCO Meeting ...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...
Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results